

PRIOR AUTHORIZATION POLICY

- POLICY:** Topical Retinoids – Tretinoin Products Prior Authorization Policy
- Single-entity topical tretinoin products
- Altreno™ (tretinoin lotion – Bausch Health)
 - Atralin™ (tretinoin gel – Valeant, generic)
 - Avita® (tretinoin cream, gel – Mylan, generic [Avita gel 0.025% is brand only])
 - Retin-A® (tretinoin cream, gel – Bausch Health, generic)
 - Retin-A Micro® (tretinoin gel microsphere – Valeant, generic)
 - Retin-A Micro® Pump (tretinoin gel microsphere – Valeant, generic [Retin-A Micro 0.06% gel and 0.08% gel are branded products only])
 - Tretin•X® (tretinoin cream – Onset Dermatologicals) [obsolete as of 08/19/2021]
- Combination topical tretinoin products
- Twyneo® (tretinoin 0.1% and benzoyl peroxide 3% cream – Sol-Gel Technologies)
 - Veltin™ (clindamycin phosphate 1.2% and tretinoin 0.025% gel – Almirall)
 - Ziana® (clindamycin phosphate 1.2% and tretinoin 0.025% gel – Valeant, generic)

REVIEW DATE: 08/04/2021; selected revision 12/22/2021, 03/09/2022

OVERVIEW

All of the single-entity and combination topical tretinoin products in this policy are indicated for the topical treatment of **acne vulgaris**.¹⁻¹⁰

Topical tretinoin products have been used to treat numerous other medical skin conditions in addition to acne vulgaris.^{1,2} Some indications have minimal published clinical data and thus appear experimental. Topical tretinoin products have also been used to treat a variety of cosmetic skin conditions, such as wrinkles, stretch marks, liver spots, premature aging, and photo-aged or photo-damaged skin.²

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of single-entity and combination topical tretinoin products. All approvals are provided for the duration noted below.

Automation: An age edit targeting patients > 30 years of age is recommended to monitor for appropriate use and to screen for cosmetic use. For patients > 30 years of age, coverage will be determined by the Prior Authorization criteria. For patients ≤ 30 years of age, coverage will be approved at the point of service.

RECOMMENDED AUTHORIZATION CRITERIA

- I. Coverage of single-entity topical tretinoin products is recommended in those who meet one of the following criteria:

FDA-Approved Indication

1. **Acne Vulgaris.** Approve for 1 year.
-

Other Uses with Supportive Evidence

2. Treatment of Other Non-Cosmetic Conditions. Approve for 1 year.

Note: Examples of other non-cosmetic conditions include acne rosacea, actinic keratosis/treatment of precancerous lesions, ichthyosis, diabetic foot ulcers, mucositis, warts, lichen planus, lichen sclerosis, pseudofolliculitis, oral leukoplakia, molluscum contagiosum, Darier's disease (keratosis follicularis), dermatitis/eczema, folliculitis, keratosis pilaris, basal cell carcinoma (skin cancer), confluent and reticulated papillomatosis, and cutis laxa.

II. Coverage of combination topical tretinoin products (Twynéo; Veltin; Ziana, generic) is recommended in those who meet the following criteria:

FDA-Approved Indication

1. Acne Vulgaris. Approve for 1 year.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of single-entity and combination topical tretinoin products is not recommended in the following situations:

1. Cosmetic Conditions. Cosmetic use is not recommended for coverage as this indication is excluded from coverage in a typical pharmacy benefit.

Note: Examples of cosmetic conditions include liver spots, stretch marks, scarring, solar elastosis, premature aging, treatment of photo-aged or photo-damaged skin, solar lentigines, skin roughness, mottled hyperpigmentation, age spots, wrinkles, geographic tongue, hyperpigmentation (caused by folliculitis, acne, or eczema), melasma/cholasma, alopecia androgenetic, alopecia areata, seborrheic keratosis, milia, nevus, poikiloderma (of Civatte), purpura (actinic/solar), keloids, and sebaceous hyperplasia.

2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Facts and Comparisons® Online. Wolters Kluwer Health, Inc.; 2020. Available at: <http://online.factsandcomparisons.com/login.aspx?url=/index.aspx&qs=>. Accessed on July 27, 2021. Search term: tretinoin.
 2. DRUGDEX® System. Thomson Reuters (Healthcare) Inc. Available at: <http://www.micromedexsolutions.com/micromedex2/librarian/>. Accessed on July 27, 2021. Search term: tretinoin.
 3. Altreno™ lotion [prescribing information]. Bridgewater, NJ: Bausch Health; March 2020.
 4. Atralin™ gel [prescribing information]. Bridgewater, NJ: Valeant; July 2016.
 5. Avita® cream and gel [prescribing information]. Morgantown WV: Mylan; June 2018.
 6. Retin-A® gel and cream. [prescribing information]. Bridgewater, NJ: Bausch Health; September 2019.
 7. Retin-A Micro® gel. [prescribing information]. Bridgewater, NJ: Valeant; July 2017.
 8. Twynéo® cream [prescribing information]. Whippany, NJ; Sol-Gel Technologies; July 2021.
 9. Veltin™ gel [prescribing information]. Malvern PA: Almirall; June 2019.
 10. Ziana® gel [prescribing information]. Bridgewater, NJ: Valeant; March 2017.
-